Vous n'êtes pas encore inscrit ?Inscription
“TOLREMO’s drug candidates aim to complement standard cancer therapies to offer better response rates, longer survival and an improved quality of life. In addition to combination therapies, we investigate our drug candidates for having efficacy as stand-alone agents in cancer indications of defined transcriptomes.
TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of resistance-preventing precision therapies to patients with cancer. Our drug development programs are supported by novel transcriptome-based bioinformatics strategies to guide preclinical translation and clinical development.” from tolremo.com